|Slideshows|March 16, 2022

Bipolar Disorder: Sorting Out Comorbidities

Because patients with bipolar disorder often have underlying comorbidities, a thorough diagnosis is imperative.

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Subscribe

Related Content

Brain Trust: Rapid Cycling, Lithium, and the Landscape of Bipolar Disorder With David Dunner, MD

ByJoseph F. Goldberg, MD,David Dunner, MD, FACPsych

May 13th 2026

Brain Trust: Treating Bipolar Disorder, Early Intervention, and the Role of Lithium With Robert M. Post, MD

ByJoseph F. Goldberg, MD,Robert M. Post, MD

March 16th 2026

FDA Approves Bysanti for Treatment of Bipolar 1 Disorder and Schizophrenia

ByJessica Walters

February 20th 2026

FDA Approves Uzedy Once-Monthly Extended Release Injectable Suspension for Bipolar I Disorder

ByLeah Kuntz

October 16th 2025

FDA Approves Risperidone Extended-Release Injectable Suspension

ByJessica Walters

September 9th 2025

Latest CME

Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Video

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

John Koo, MD; T.J. Chao, MPAS, PA-C

Video

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Ilan Melnick, MD; Linda Collado, MD, DABPN, FAPA; Maria Collado, MD, FAPA

Video

Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Patricia Junquera, MD; Maria Collado, MD; Erin C. Crown, MHSPAS, PA-C, Psych-CAQ

Video

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Juan D. Oms, MD, FAPA; Linda Collado, MD, DABPN, FAPA; Ginger Shupe, MD

Video

(CPE Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Bipolar Disorder: Sorting Out Comorbidities

Related Content

Brain Trust: Rapid Cycling, Lithium, and the Landscape of Bipolar Disorder With David Dunner, MD

Brain Trust: Treating Bipolar Disorder, Early Intervention, and the Role of Lithium With Robert M. Post, MD

FDA Approves Bysanti for Treatment of Bipolar 1 Disorder and Schizophrenia

FDA Approves Uzedy Once-Monthly Extended Release Injectable Suspension for Bipolar I Disorder

FDA Approves Risperidone Extended-Release Injectable Suspension

Latest CME

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

(CPE Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Trending on Psychiatric Times

PET Imaging Confirms Lower Muscarinic M1 Receptor Availability in Schizophrenia

What's New in Psychiatric Treatment? Highlights From the 2026 Southern California Psychiatry Conference

A New Mechanism for ADHD: Raman Baweja, MD, on Centanafadine's FDA Approval

From Fibromyalgia to Depression: TNX-102 Sublingual Cyclobenzaprine Trials for MDD

This Month In Alzheimer Disease: July’s Pharmacology and Research Developments